Literature DB >> 34525843

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG.

Shuhong Ma1,2,3,4, Wenjian Jiang3,4, Xujie Liu5, Wen-Jing Lu1,2, Tao Qi6, Jingjing Wei7,6, Fujian Wu3,4, Yun Chang3,4, Siyao Zhang3,4, Yabing Song7, Rui Bai3,4, Jianbing Wang, Andrew S Lee8,9, Hongjia Zhang3,4, Yongming Wang6, Feng Lan2,3,4,5.   

Abstract

[Figure: see text].

Entities:  

Keywords:  base editor; gene therapy; genome editing; hypertrophic cardiomyopathy

Mesh：

Substances：

Year:  2021        PMID： 34525843     DOI： 10.1161/CIRCRESAHA.120.318674

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


  4 in total

1.  AKT-mTOR signaling-mediated rescue of PRKAG2 R302Q mutant-induced familial hypertrophic cardiomyopathy by treatment with β-adrenergic receptor (β-AR) blocker metoprolol.

Authors:  Jian Zhuo; Haihua Geng; Xiaohui Wu; Mengkang Fan; Hongzhuan Sheng; Jian Yao
Journal:  Cardiovasc Diagn Ther       Date:  2022-06

Review 2.  CRISPR Modeling and Correction of Cardiovascular Disease.

Authors:  Ning Liu; Eric N Olson
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 3.  The use of new CRISPR tools in cardiovascular research and medicine.

Authors:  Masataka Nishiga; Chun Liu; Lei S Qi; Joseph C Wu
Journal:  Nat Rev Cardiol       Date:  2022-02-10       Impact factor: 49.421

4.  Rare Genetic Variants Associated With Myocardial Fibrosis: Multi-Ethnic Study of Atherosclerosis.

Authors:  Mahsima Shabani; Diptavo Dutta; Bharath Ambale-Venkatesh; Wendy S Post; Kent D Taylor; Stephen S Rich; Colin O Wu; Naveen L Pereira; Sanjiv J Shah; Nilanjan Chatterjee; Jerome I Rotter; Dan E Arking; Joao A C Lima
Journal:  Front Cardiovasc Med       Date:  2022-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.